What the Research Says About SS-31: Studied Benefits, Evidence Grades and Open Questions

Reviewed for accuracy by the Gorilla Research Labs research team · 2026-07-04

RESEARCH What the Research Says About SS-31: Studied Benefits, Evidence Grades and Open Questions SS-31, also known as elamipretide, is a mitochondria-targeted peptide designed to interact with the inner mitochondrial membrane to stabilize cardiolipin. Research into this compound spans from fundamental molecular interactions in vitro to clinical trials investigating its impact on mitochondrial function in specific patient populations. Compound identity: CAS 736992-21-5 · C32H49N9O5 · 639.8 g/mol (verified via PubChem)

The Mechanism: Cardiolipin Stabilization

At the heart of SS-31 research is its interaction with cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for the structural integrity of the cristae ^[1]. In vitro studies have demonstrated that SS-31 binds to cardiolipin, preventing its oxidation and maintaining the structural organization of the electron transport chain complexes ^[1]. By stabilizing these cardiolipin-cytochrome c complexes, the peptide aims to prevent the peroxidase activity of cytochrome c, which is a known driver of mitochondrial dysfunction under oxidative stress ^[1]. This mechanism-only evidence provides the foundational rationale for why researchers investigate the peptide in models of mitochondrial impairment.

Mitochondrial Myopathy and Human Clinical Data

The translation of SS-31 from cellular models to human subjects has been a primary focus of clinical research, particularly in the context of primary mitochondrial myopathy (PMM). In a randomized, double-blind, placebo-controlled phase 2 trial, investigators assessed the impact of the peptide on exercise capacity and patient-reported outcomes in individuals with genetically confirmed PMM ^[2]. While the study provided insights into the safety and tolerability of the compound in this population, the primary endpoint—the change in the 6-minute walk distance—did not reach statistical significance compared to the placebo group ^[2]. This highlights the complexity of translating mitochondrial stabilization into measurable functional improvements in human clinical settings.

Barth Syndrome and Accelerated Approval

One of the most significant milestones for SS-31 (elamipretide) is its regulatory history regarding Barth syndrome, a rare genetic disorder characterized by cardiolipin deficiency. The FDA granted accelerated approval for the use of elamipretide in the treatment of Barth syndrome in patients aged 12 years and older ^[4]. This approval was based on evidence demonstrating an increase in cardiac stroke volume, a measure of heart function, in patients receiving the treatment ^[4]. Because this was an accelerated approval, the evidence is tied to a specific, defined population where the underlying pathophysiology is directly linked to the cardiolipin-stabilizing mechanism of the peptide ^[4].

Geographic Atrophy and ReCLAIM-2

The research scope for SS-31 has extended into ophthalmology, specifically targeting dry age-related macular degeneration (AMD) associated with geographic atrophy. The ReCLAIM-2 phase 2 clinical trial investigated the efficacy and safety of the peptide in patients with this condition ^[3]. The study evaluated changes in the area of geographic atrophy over time ^[3]. The ReCLAIM-2 trial did not meet its primary endpoint of reducing the rate of geographic atrophy lesion growth compared to sham ^[3]. The ReCLAIM-2 trial results highlight the difficulty of demonstrating clinical efficacy in slowing the progression of geographic atrophy ^[3].

Unanswered Questions and Research Gaps

While the interaction between SS-31 and cardiolipin is well-documented in vitro, many questions regarding its long-term systemic effects remain open ^[1]. The clinical trials conducted to date have focused on specific, often rare, mitochondrial-linked conditions, meaning there is limited data regarding the compound's effects in broader, healthy, or non-pathological populations ^[2], ^[3]. Furthermore, the variability in clinical trial outcomes—ranging from the cardiac improvements seen in Barth syndrome to the lack of significant exercise capacity changes in PMM—suggests that the peptide’s efficacy may be highly dependent on the specific underlying mitochondrial defect ^[2], ^[4]. Future research is required to determine the durability of these effects and the optimal parameters for mitochondrial modulation.

Frequently asked questions

How does SS-31 interact with cardiolipin? Research indicates that SS-31 binds to cardiolipin in the inner mitochondrial membrane, which helps to stabilize the structure of the membrane and prevents the peroxidase activity of cytochrome c ^[1]. This is a mechanism-only finding observed in laboratory settings ^[1]. Has SS-31 been approved by the FDA? Yes, the FDA granted accelerated approval to elamipretide (SS-31) for the treatment of Barth syndrome in patients aged 12 years and older ^[4]. This approval is specific to that defined patient population ^[4]. What did the ReCLAIM-2 trial show? The ReCLAIM-2 phase 2 trial evaluated the use of SS-31 in patients with geographic atrophy associated with dry AMD ^[3]. The study gathered data on the progression of the condition, contributing to the clinical evidence base for the compound in ocular research ^[3]. Did SS-31 improve exercise capacity in mitochondrial myopathy? In a randomized, placebo-controlled trial involving patients with primary mitochondrial myopathy, the peptide did not demonstrate a statistically significant improvement in the 6-minute walk distance compared to the placebo ^[2]. What is the evidence grade for SS-31's mitochondrial benefits? The evidence is mixed: there is strong mechanism-only evidence regarding cardiolipin stabilization ^[1], clinical evidence from human trials regarding safety and specific functional outcomes in rare diseases ^[2], ^[3], and regulatory evidence supporting its use in Barth syndrome ^[4]. SS-31 is a mitochondria-targeted peptide that binds to cardiolipin to prevent its oxidation and stabilize mitochondrial cristae ^[1]. A Certificate of Analysis (COA) is generated for each batch, documenting these results alongside assessments for residual solvents and heavy metals. By utilizing lot-tracking systems, researchers ensure that the material used in experiments is consistent and traceable back to the original synthesis, allowing for reproducibility in future studies. Research use only. The compounds discussed are supplied for laboratory research and are not for human or veterinary use. Nothing on this page is medical advice, a dosing guide, or a claim about any product sold here; it summarises published research and cites its sources.